|
|
|
|
 |
Hi ,
|
This week’s digest is brought to you by Main Sequence, Australia’s deep tech investment fund. Main Sequence tackles the world’s biggest challenges by turning today’s scientific discoveries into tomorrow’s industries. It works closely with scientists, researchers, and industry collaborators to create, fund, and accelerate new companies and industries that accelerate humanity for a more prosperous future.
|
|
|
|
|
|
|
Join Synonym, in collaboration with EV Biotech, Vectron Biosolutions, SynBioBeta, and Enduro Genetics, for
an insightful discussion on the critical role of strain engineering in the commercialization of bioproducts. Synonym and BCG’s recent report reveals that economies of scale alone are insufficient for commercializing industrial bioproducts. An expert panel will explore the significance of strain optimization and its impact on increasing productivity, enhancing product quality, and achieving cost efficiency in biomanufacturing processes.
📅 Date: July 17, 2024
🕒 Time: 4 pm to 5 pm CET
📍 Register here: https://zoom.us/webinar/register/WN_G1bwofYRTgOTKpZCLTAXkA
John Cumbers has always been passionate about the emerging bioeconomy and its potential. His new venture, Biological Enlightenment Studios, aims to ignite a sense of wonder and curiosity about molecular biology in the minds of young explorers everywhere. Their debut project, Lee's Lab, is an animated series that follows 12-year-old Lee on her thrilling adventures through the jungles of Borneo. Along the way, she'll uncover the mysteries of molecular biology and the beauty of biodiversity. It's their goal to inspire a new generation to embrace the marvels of biology and understand the importance of bioliteracy for the future of our bioeconomy. Tune in to The Bio Report's latest podcast episode to hear more about his journey with Biological Enlightenment Studios and why he is passionate about sparking imagination and knowledge in the young minds of today.
|
|
Experience SynBioBeta 2025 your way!
|
|
|
Our new Expo Hall Pass is your budget-friendly gateway to
innovation. It offers a firsthand look at cutting-edge technologies on the exhibit floor, valuable networking opportunities, and access to our partnering app.
Ready to dive deeper? Upgrade to our Conference Pass and unlock the full potential of your SynBioBeta experience. This premium option includes everything in the Expo Hall Pass, plus access to main stage sessions, breakout discussions, and hands-on workshops - your complete ticket to the forefront of synthetic biology.
|
|
|
Click here to learn more, but decide soon! Pricing will increase soon.
|
|
Join our rapidly growing synthetic biology community at SynBioBeta 2025. We aim to bring even more diverse voices to the forefront of the conversation around synthetic biology, and we are looking for speakers to share their expertise, spark thoughtful discussions, and lead education sessions for various aspects of SynBio.
|
Latest Video From SynBioBeta 2024:
|
 |
Applications of AI are exploding in tech. Underpinning these applications are open platforms and services providing reinforcement learning. If biotech wants to move as fast as tech, we must take a page out of Silicon Valley's book: open platforms that companies can innovate on directly and easy access to experimental data to reinforce foundational models. Ginkgo Bioworks aims to do just that through their strategic partnership with Google Cloud, their growing trove of metagenomic and experimental data, plus their newest offering democratizing access to their Foundry, Lab Data as a Service. Click here to watch the video.
|
Insights:
|
Remember the ‘Big Data’ Problem? Yeah, Me Neither. The big data problem of the mid-00s has shifted to a small data issue, where synthetic biologists, with high-throughput testing platforms and multimodal datasets, are uniquely equipped to provide the necessary data for training machine learning models.
|
Industry News:
|
|
|
Additional Industry News:
|
|
Regards
Jeff
Jeffrey S. Buguliskis, PhD
Director of Content, SynBioBeta
|
Who's hiring?
|
|
|
|
|
|
|
|
|
|
